Acornmed
Haidian
About Acornmed
Acornmed provides tumor genetic testing and detection solutions intended to provide clinical solutions with genomics as the core of tumor precision medicine. It also provides advanced molecular diagnosis for solid and blood tumor genetic testing, enabling cancer patients to receive comprehensive and personalized early detection test results.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $28.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2022)
- Website: acornmed.com
- Phone: 010-53606156
Industries & Categories
Oncology
Social Profiles
Canonical: https://fsome.com/organization/acornmed-139103 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.